Canadian Court Upholds New Drug Price Comparison Basket – With Caveats
Executive Summary
A Canadian court has dismissed an appeal brought by industry challenging new pricing rules that introduce a revised basket of reference countries as part of cost-containment measures.
You may also be interested in...
Canada’s Controversial Pricing Guidelines Suspended
The implementation of new pricing guidelines that are unpopular with the pharmaceutical has been put on hold, to the relief of the pharmaceutical industry.
Canada’s Drug Pricing Reform Faces Legal Challenge
Canada’s R&D drug industry says it approached the court as a “necessary step,” given the significant impact of the pricing reforms.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.